NAV

Otilonium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Otilonium is a spasmolytic medication used to treat irritable bowel syndrome (IBS).

Generic Name
Otilonium
DrugBank Accession Number
DB13500
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Similar Structures
Weight
Average: 483.672
Monoisotopic: 483.321734293
Chemical Formula
C29H43N2O4
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination for symptomatic treatment ofGastrointestinal painCombination Product in combination with: Simethicone (DB09512)••••••••••••••••••
Used in combination for symptomatic treatment ofGastrointestinal painCombination Product in combination with: Simethicone (DB09512)••••••••••••••••••
Used in combination for symptomatic treatment ofPainCombination Product in combination with: Simethicone (DB09512)••••••••••••••••••
Used in combination for symptomatic treatment ofSpasmsCombination Product in combination with: Simethicone (DB09512)••••••••••••••••••
Used in combination for symptomatic treatment ofSpasmsCombination Product in combination with: Simethicone (DB09512)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbametapirThe serum concentration of Otilonium can be increased when it is combined with Abametapir.
AcarboseThe risk or severity of hypoglycemia can be increased when Otilonium is combined with Acarbose.
AcebutololAcebutolol may increase the arrhythmogenic activities of Otilonium.
AceclofenacThe risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Otilonium.
AcemetacinThe risk or severity of hyperkalemia can be increased when Otilonium is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Otilonium bromide21HN3N72PV26095-59-0VWZPIJGXYWHBOW-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DOLOSPAS 40 MG/80 MG FİLM KAPLI TABLET, 30 ADETOtilonium bromide (40 mg) + Simethicone (80 mg)TabletTRIPHARMA İLAÇ SAN. VE TİC. A.Ş.2016-11-03Not applicableTurkey flag
DOLOSPAS 40 MG/80 MG FİLM KAPLI TABLET, 90 ADETOtilonium bromide (40 mg) + Simethicone (80 mg)TabletTRIPHARMA İLAÇ SAN. VE TİC. A.Ş.2016-11-03Not applicableTurkey flag
PİNİX 40 MG/80 MG FİLM KAPLI TABLET, 30 TABLETOtilonium bromide (40 mg) + Simethicone (80 mg)Tablet, coatedOralSANTA FARMA İLAÇ SAN. A.Ş.2019-01-11Not applicableTurkey flag
SIMFLAT 40MG/80 MG FİLM KAPLI TABLET, 30 ADETOtilonium bromide (40 mg) + Simethicone (80 mg)Tablet, film coatedABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.2014-02-19Not applicableTurkey flag
SIMFLAT 40MG/80 MG FİLM KAPLI TABLET, 90 ADETOtilonium bromide (40 mg) + Simethicone (80 mg)Tablet, film coatedABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş.2014-02-19Not applicableTurkey flag

Categories

ATC Codes
A03CA04 — Otilonium bromide and psycholepticsA03AB06 — Otilonium bromide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Benzoic acid esters / Benzamides / Benzoyl derivatives / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Tetraalkylammonium salts / Carboxylic acid esters / Secondary carboxylic acid amides / Monocarboxylic acids and derivatives
show 6 more
Substituents
Alkyl aryl ether / Amine / Aromatic homomonocyclic compound / Benzamide / Benzanilide / Benzoate ester / Benzoic acid or derivatives / Benzoyl / Carboxamide group / Carboxylic acid derivative
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6330179ARU
CAS number
105360-89-2
InChI Key
NQHNLNLJPDMBFN-UHFFFAOYSA-O
InChI
InChI=1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1
IUPAC Name
diethyl(methyl)(2-{4-[2-(octyloxy)benzamido]benzoyloxy}ethyl)azanium
SMILES
CCCCCCCCOC1=CC=CC=C1C(=O)NC1=CC=C(C=C1)C(=O)OCC[N+](C)(CC)CC

References

General References
  1. Evangelista S, Traini C, Vannucchi MG: Otilonium Bromide: A Drug with a Complex Mechanism of Action. Curr Pharm Des. 2018;24(16):1772-1779. doi: 10.2174/1381612824666180507122935. [Article]
  2. Evangelista S: Otilonium bromide: a selective spasmolytic for the gastrointestinal tract. J Int Med Res. 1999 Sep-Oct;27(5):207-22. doi: 10.1177/030006059902700501. [Article]
  3. TITCK Product Information: Motigen (otilonium bromide) film-coated tablets for oral use [Link]
  4. TITCK Product Information: Pinix (otilonium bromide/simethicone) film-coated tablets for oral use [Link]
ChemSpider
65078
RxNav
32311
ChEBI
135780
ChEMBL
CHEMBL1433361
ZINC
ZINC000008214636
PDBe Ligand
7TB
Wikipedia
Otilonium_bromide
PDB Entries
7wlk

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticGastroscopy1
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
Not AvailableCompletedTreatmentIrritable Bowel Syndrome (IBS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Tablet, coatedOral40 mg
Tablet
Tablet, film coatedOral40 mg
Tablet, film coatedOral4000000 mg
TabletOral40.000 mg
Tablet, film coatedOral
Tablet, coatedOral40 g
TabletOral40.00 mg
Tablet, film coated
TabletOral40 mg
Powder, for solution
Suppository
Tablet, coatedOral
Tablet, coatedOral
Powder
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.42e-05 mg/mLALOGPS
logP2.92ALOGPS
logP2.58Chemaxon
logS-7.3ALOGPS
pKa (Strongest Acidic)12.75Chemaxon
pKa (Strongest Basic)-3.9Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area64.63 Å2Chemaxon
Rotatable Bond Count17Chemaxon
Refractivity155.79 m3·mol-1Chemaxon
Polarizability58.63 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-245.0123676
predicted
DarkChem Lite v0.1.0
[M-H]-226.99092
predicted
DeepCCS 1.0 (2019)
[M+H]+245.3246676
predicted
DarkChem Lite v0.1.0
[M+H]+229.34895
predicted
DeepCCS 1.0 (2019)
[M+Na]+245.3181676
predicted
DarkChem Lite v0.1.0
[M+Na]+235.91072
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [Article]

Drug created at June 23, 2017 20:43 / Updated at May 14, 2021 01:06